Part 5/9:
As GW Pharmaceuticals positions itself for entry into the U.S. market, it faces the challenge of competition from other treatments, including options developed by companies focusing on alternative therapies for epilepsy. The financial winds have already lifted GW's stock value significantly, highlighting investor enthusiasm. Nevertheless, analysts caution that the current market cap may reflect excessive optimism, particularly against the backdrop of broader marijuana stock hype.